A Phase 3 interventional study of OLZ/SAM and Olanzapine in Schizophrenia and Bipolar I Disorder, sponsored by Alkermes, Inc.. Recruiting at 47 sites in 5 countries. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Alkermes, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Schizophrenia by Alkermes, Inc. — 2 open to participants now, 2 under way, 2 of them phase 3. Schizophrenia · Alkermes, Inc..
Among the 21 studies in Schizophrenia by Alkermes, Inc., this one is the 13th largest by planned enrollment of the 19 interventional ones that give a count, is the only one that started in 2022, is one of 12 in phase 3, and was the 20th registered.
3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →2 of the 21 studies in Schizophrenia by Alkermes, Inc. are open now, in 5 countries. Recruiting first, the newest first:
Alkermes, Inc. · Sites in United States, Argentina, Brazil and 2 more countries
Ages 10–17
By country, each count listing its studies:
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 10 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 220 is above the median of 70 across 2,952 interventional studies indexed under Schizophrenia.
Median enrollment 281 across the 19 interventional studies, 338 across the 1 observational. Of the 18 that completed or were terminated, 13 (72%) have results posted.
This tab as a report to print or save as PDF → With an account.
Alkermes, Inc. is the lead sponsor of 83 studies on the registry; 9 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 5 (56%) have results posted.
1 of the studies in Schizophrenia by Alkermes, Inc. that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04987229Phase 3Alkermes, Inc.Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 21 studies in Schizophrenia by Alkermes, Inc., from their registry updates:
This tab as a report to print or save as PDF → With an account.
To compare changes in body mass index (BMI) Z-score following treatment with OLZ/SAM vs olanzapine
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Fixed dose combination of olanzapine and samidorphan
Drug: OLZ/SAM
Fixed dose of olanzapine
Drug: Olanzapine
Drug page: S-AdenosylmethionineStudies of S-AdenosylmethionineS-Adenosylmethionine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
OLZ/SAM refers to the fixed dose combination of olanzapine and samidorphan. The starting dose of olanzapine will be 2.5 mg/day or 5 mg/day at the discretion of the Investigator with a maximum daily dose of 20mg/day. The starting dose of samidorphan will be 5 or 10 mg.
Also known as: ALKS 3831, LYBALVI
The starting dose of olanzapine will be 2.5 mg/day or 5 mg/day at the discretion of the Investigator with a maximum daily dose of 20mg/day
Change from baseline in body mass index (BMI) Zscore at week 12
To compare changes in body mass index (BMI) Z-score following treatment with OLZ/SAM vs olanzapine
Time frame: 12 weeks
Proportion of subjects with >=0.5 increase in BMI Z-score at Week 12
To compare subjects with clinical significant BMI Z-score increase with OLZ/SAM vs olanzapine
Time frame: 12 weeks
Time to all-cause discontinuation of study drug over 52 weeks
To compare time to all-cause discontinuation of study drug with OLZ/SAM vs olanzapine
Time frame: Up to 52 weeks
Change from baseline in waist circumference
To compare the change from baseline in waist circumference with OLZ/SAM vs olanzapine
Time frame: 12 weeks
Change from baseline in Positive and Negative Syndrome Scale (PANSS) total score for patients with schizophrenia by visit
To compare the change from baseline in Positive and Negative Syndrome Scale (PANSS) total score with OLZ/SAM vs olanzapine for patients with schizophrenia
Time frame: 12 weeks
Change from baseline in Young Mania Rating Scale (YMRS) in patients with Bipolar I disorder
To compare the change from baseline in YMRS with OLZ/SAM vs olanzapine for patients with bipolar I disorder
Time frame: 12 weeks
Change from baseline in Children's Depression Rating Scale-Revised (CDRS-R) for patients with bipolar I disorder by visit
To compare the change from baseline in CDRS-R with OLZ/SAM vs olanzapine for patients with bipolar I disorder
Time frame: 12 weeks
Incidence of Adverse Events
Time frame: Up to 52 weeks
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jun 2022 (actual). Primary completion is estimated for Dec 2027, 66 months after the start.
Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's planned 66 months is above that.
Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: primary completion Sep 2026 → Dec 2027 and completion Sep 2026 → Dec 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: S-Adenosylmethionine